HSBC Holdings Portfolio holdings
HSBC Holdings plc, founded in 1865 as the Hongkong and Shanghai Banking Corporation by Sir Thomas Sutherland to finance trade in East Asia, is a British multinational bank headquartered in London, managing trillions in assets as one of the world’s largest banking and financial services organizations. Operating in over 60 countries with a strong emphasis on Asia—where it generates much of its revenue—HSBC offers retail banking, wealth management, commercial banking, and global markets services to more than 40 million customers, supported by around 214,000 employees as of late 2024. Known for its international network and resilience through crises like the 1997 Asian financial downturn, HSBC has pivoted under Group CEO Noel Quinn (since 2020) to accelerate digital transformation and sustainability goals, targeting net-zero emissions by 2050. Despite challenges like geopolitical tensions and regulatory pressures, HSBC remains a cornerstone of global finance, leveraging its heritage as a trade financier into a modern, Asia-centric banking powerhouse.
Top Buys
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$511M |
| 2 |
Energy Select Sector SPDR Fund
XLE
|
+$285M |
| 3 |
Apple
AAPL
|
+$273M |
| 4 |
Meta Platforms (Facebook)
META
|
+$265M |
| 5 |
Microsoft
MSFT
|
+$227M |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
+$916M |
| 2 |
NVIDIA
NVDA
|
+$768M |
| 3 |
Alibaba
BABA
|
+$275M |
| 4 |
Uber
UBER
|
+$222M |
| 5 |
Adobe
ADBE
|
+$206M |
Sector Composition
| 1 | Technology | 30.92% |
| 2 | Financials | 13.84% |
| 3 | Consumer Discretionary | 11% |
| 4 | Healthcare | 9.89% |
| 5 | Communication Services | 9.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Lineage Cell Therapeutics
LCTX
$306M
| $9.84K | ﹤0.01% |
20,960
+3,572
| +21% | +$1.68K |
|
2527
Lyell Immunopharma
LYEL
$246M
| $9.67K | ﹤0.01% |
936
-6
| -0.6% | -$62 |
|
2528
ALX Oncology
ALXO
$56.8M
| $9.66K | ﹤0.01% |
16,128
-26
| -0.2% | -$16 |
|
2529
FibroGen
FGEN
$48.6M
| $9.51K | ﹤0.01% |
1,199
-889
| -43% | -$7.05K |
|
2530
NextCure
NXTC
$14.5M
| $8.45K | ﹤0.01% |
1,438
-9
| -0.6% | -$53 |
|
2531
SES AI
SES
$456M
| $8.23K | ﹤0.01% |
15,498
+171
| +1% | +$91 |
|
2532
Forge Global Holdings
FRGE
$239M
| $7.91K | ﹤0.01% |
903
+3
| +0.3% | +$26 |
|
2533
Rallybio
RLYB
$25.1M
| $7.89K | ﹤0.01% |
12,054
-2,024
| -14% | -$1.33K |
|
2534
Lexicon Pharmaceuticals
LXRX
$418M
| $7.76K | ﹤0.01% |
13,415
-87
| -0.6% | -$50 |
|
2535
Veru
VERU
$50.5M
| $7.57K | ﹤0.01% |
1,544
-10
| -0.6% | -$49 |
|
2536
Lunai Bioworks Inc. Common Stock
RENB
$45.9M
| $7.38K | ﹤0.01% |
13,134
-337
| -3% | -$189 |
|
|
KG
2537
Kestrel Group, Ltd.
KG
$211M
| $6.23K | ﹤0.01% |
521
+5
| +1% | +$60 |
|
2538
Applied Therapeutics
APLT
$60.6M
| $5.5K | ﹤0.01% |
11,405
+133
| +1% | +$64 |
|
|
ADAP
2539
Adaptimmune Therapeutics
ADAP
$14.8M
| $5.22K | ﹤0.01% |
26,064
| – | – |
|
|
OPI
2540
Office Properties Income Trust
OPI
$40.8M
| $5.12K | ﹤0.01% |
11,080
| – | – |
|
2541
X4 Pharmaceuticals
XFOR
$73.2M
| $4.7K | ﹤0.01% |
664
+6
| +0.9% | +$42 |
|
2542
Mersana Therapeutics
MRSN
$35.6M
| $4.38K | ﹤0.01% |
500
-32
| -6% | -$280 |
|
2543
LanzaTech
LNZA
$45.1M
| $3.68K | ﹤0.01% |
131
-1
| -0.8% | -$28 |
|
2544
Celsius Holdings
CELH
$14.9B
| $362 | ﹤0.01% |
10
-3,765
| -100% | -$136K |
|
2545
PotlatchDeltic
PCH
$3.2B
| – | – |
-42,994
| Closed | -$1.68M |
|
2546
Philips
PHG
$26.8B
| – | – |
-125,335
| Closed | -$3.04M |
|
2547
Powell Industries
POWL
$3.47B
| – | – |
-1,423
| Closed | -$320K |
|
|
PPTA
2548
Perpetua Resources
PPTA
$1.86B
| – | – |
-12,144
| Closed | -$128K |
|
2549
Permian Resources
PR
$9.63B
| – | – |
-152,288
| Closed | -$2.2M |
|
2550
Portillo's
PTLO
$441M
| – | – |
-19,803
| Closed | -$184K |
|